Roscoe Morton, MD
Medical Oncology · Clive, IANPI 1447215629
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations.
Across 163 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$454
- Johnson & Johnson$386
- Gilead$231
- Novartis$216
- Incyte Corporation$187
- Bristol Myers Squibb$130
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,424100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 21 | $454 |
| Johnson & Johnson | 16 | $386 |
| Gilead(2 entities) | 11 | $231 |
| Novartis | 9 | $216 |
| Incyte Corporation | 9 | $187 |
| Bristol Myers Squibb | 6 | $130 |
| Servier Pharmaceuticals LLC | 5 | $110 |
| Daiichi Sankyo Inc. | 6 | $100 |
| Beigene USA, Inc. | 4 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $85 |
| EMD Serono, Inc. | 4 | $79 |
| Tersera Therapeutics LLC | 3 | $73 |
| Pfizer | 4 | $71 |
| Bayer | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 3 | $67 |
| Lilly USA, LLC | 4 | $66 |
| Seagen Inc. | 4 | $65 |
| Exelixis Inc. | 3 | $63 |
| GSK | 4 | $62 |
| Pharmacosmos Therapeutics Inc. | 3 | $61 |
| Genmab U.S., Inc. | 2 | $61 |
| Blueprint Medicines Corporation | 2 | $57 |
| Jazz Pharmaceuticals Inc. | 3 | $56 |
| Amgen | 3 | $56 |
| Genentech USA, Inc. | 3 | $54 |
| AbbVie | 2 | $50 |
| Eisai Inc. | 3 | $49 |
| Tempus AI, Inc | 3 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Merck | 2 | $43 |
| Agios Pharmaceuticals, Inc. | 2 | $40 |
| AVEO Pharmaceuticals, Inc. | 1 | $40 |
| Sanofi | 1 | $38 |
| Mirati Therapeutics, Inc. | 2 | $37 |
| Deciphera Pharmaceuticals Inc. | 1 | $24 |
| Beone Medicines USA, Inc. | 1 | $18 |
| Sirtex Medical Inc | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| ADC Therapeutics America, Inc. | 1 | $14 |
How this compares
$3,436 in reported general payments places this provider in the 70th percentile of 47 medical oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 23 | $73,432 |
| Hydroxyurea | 27 | $882 |
| Tamoxifen Citrate | 15 | $359 |
| Prednisone | 34 | $172 |
| Ondansetron Hcl | 12 | $122 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Clive
- Tara GraffClive$702K
- Amy HughesClive$879
- Jun ZhangIowa City$377K
- Mathew WehbeDes Moines$120K
- Ann StrohCedar Rapids$65K
- Praveen VikasFairfield$30K
- Giselle MeryDes Moines$12K
- John RiethIowa City$11K
- Mark BurkardIowa City$10K
- Emily BrugioniDes Moines$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.